In patients with uncontrolled or resistant hypertension, the addition of the aldosterone synthase inhibitor baxdrostat to background antihypertensive therapy reduces seated in-office systolic blood pressure (BP) after 12 weeks of treatment. These findings come from the BaxHTN trial and were presented at the ESC Congress 2025.

This phase III trial included patients with elevated seated systolic BP (140–169 mmHg) despite receiving stable treatment with two (uncontrolled hypertension) or three or more (resistant hypertension) antihypertensive drugs. A total of 796 patients were first assigned to a 2-week run-in period in which they received placebo in addition to their background medication, after which those patients with a seated systolic BP of ≥135 mmHg and good adherence to background medication were randomly assigned to receive either 1 mg or 2 mg of baxdrostat, or placebo, once daily for 12 weeks in addition to background antihypertensive therapy.